Your browser doesn't support javascript.
loading
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Khurana, Rahul N; Oden, Neal L; VanVeldhuisen, Paul C; Scott, Ingrid U; Blodi, Barbara A; Ip, Michael S.
Affiliation
  • Khurana RN; Northern California Retina Vitreous Associates, Mountain View, CA, USA.
  • Oden NL; The Emmes Company, LLC, 401 N. Washington Street, Suite 700, Rockville, MD, 20850, USA.
  • VanVeldhuisen PC; The Emmes Company, LLC, 401 N. Washington Street, Suite 700, Rockville, MD, 20850, USA. score2@emmes.com.
  • Scott IU; Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
  • Blodi BA; University of Wisconsin Fundus Photograph Reading Center, Madison, WI, USA.
  • Ip MS; Doheny Eye Institute, University of California, Los Angeles, CA, USA.
Graefes Arch Clin Exp Ophthalmol ; 259(7): 1839-1851, 2021 Jul.
Article in En | MEDLINE | ID: mdl-33415354
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Retinal Vein Occlusion / Angiogenesis Inhibitors Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Graefes Arch Clin Exp Ophthalmol Year: 2021 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Retinal Vein Occlusion / Angiogenesis Inhibitors Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Graefes Arch Clin Exp Ophthalmol Year: 2021 Type: Article Affiliation country: United States